ClinicalTrials.gg
Active, not recruitingNCT03523377Updated Jul 1, 2026

Overnight Fasting After Completion of Therapy: The OnFACT Study

An interventional study of prolonged overnight fasting and usual care in Childhood Cancer Survivors, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test whether regularly not eating for at least 14 hours overnight ("intermittent fasting") is feasible and can improve blood sugar.

02

Conditions studied

  • Childhood Cancer Survivors

Browse trials for

Keywords

  • Fasting
  • 18-199
03

In context

Fasting

392 studies on the registry are indexed under Fasting; 63 are open to participants now.

This study's enrollment of 28 is below the median of 45 across 311 interventional studies indexed under Fasting.

Browse Fasting studies →

Lead sponsor

Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 327 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is ≥ 18.5 kg/m\^2
  • History of treatment for cancer or related illness diagnosed at ≤ 25 years old
  • Off cytotoxic therapy for primary cancer ≥ 2 years
  • Not receiving cytotoxic therapy (chemotherapy, external beam radiation therapy) at the time of study enrollment
  • History of radiation to the chest, abdomen or total body
  • Current age ≥18 years
  • English-speaking
  • Personal phone with SMS text messaging capability
  • Willingness to wear an mHealth device, such as a FitBit, for two 7-day periods
  • Able to perform all study requirements

Exclusion criteria

Exclusion Criteria:

  • Use of any antidiabetic, weight loss, or appetite control medication
  • Use of any other medication that could impact dietary intake, such as prednisone
  • Currently fasts 12 hours or more by self-report
  • Unable to fast due to medical reason such as pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    prolonged overnight fasting

    Participants randomized to the fasting arm will be instructed on how to use the SMS texting app to indicate the beginning and end of the nightly fast. In the first 2-4 weeks following the first overnight fast, intervention participants will complete three phone calls with study staff trained in motivational interviewing. These calls will be used to reinforce the prolonged overnight fasting instructions, identify barriers to prolonged overnight fasting, and support successes where they have occurred.

    Other: prolonged overnight fasting

  • Active comparator
    usual care

    Participants randomized to the usual care arm will be instructed to eat a heart-healthy diet and exercise for at least 30 minutes five days a week, which is usual counseling in our clinics.

    Other: usual care

Interventions

  • Otherprolonged overnight fasting

    Three phone calls using motivational interviewing, support via SMS text.

  • Otherusual care

    Eat a heart-healthy diet and exercise for at least 30 minutes five days a week

06

What researchers measure

Primary outcomes

  1. Participation completion

    Proportion of registered participants who successfully complete the 6-month intervention

    Time frame: 6 months

Secondary outcomes

  1. measure of glucose metabolism

    Assess the effect of prolonged overnight fasting on glucose metabolism, measured by glycosylated hemoglobin (HbA1c).

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2018 (actual). Primary completion is estimated for Apr 2027, 108 months after the start.

Of 144 non-industry interventional studies with no phase under Fasting, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 40. This study's planned 108 months is above that.

Counting every sponsor, half of 149 studies reached it within 18 months; a quarter within 6 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2018
First posted
May 14, 2018
StartActual
Apr 27, 2018
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03523377
Responsible party
Sponsor
First posted
May 14, 2018
Start date
Apr 27, 2018
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Danielle Friedman, MD, MS
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion